search buttonmobile navigation expand button

Need Assistance?

Back to Search Results


dal-GenE - A phase III, double-­‐blind, randomized placebo-­‐controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-­‐GenE trial - DAL-301
To check the effect of dalcetrapib only in patients with the AA variant of the ADCY9 gene and confirm the findings of cardiovascular benefit for this group only.  
Trial Information
Principal Investigator: Dr. Mark Zainea, MD

Contact: Study Coordinator
Phone (Main): 586-493-7509

IRB Number: McLaren Macomb 2016-00018, McLaren Bay 2016-00010 02525939

More Information: